Abstract
Cryptosporidium parvum is an apicomplexan parasite that can cause serious watery diarrhea, cryptosporidiosis, in human and other mammals. C. parvum invades gastrointestinal epithelial cells, which have abundant glycosaminoglycans on their cell surface. However, little is known about the interaction between C. parvum and glycosaminoglycans. In this study, we assessed the inhibitory effect of sulfated polysaccharides on C. parvum invasion of host cells and identified the parasite ligands that interact with sulfated polysaccharides. Among five sulfated polysaccharides tested, heparin had the highest, dose-dependent inhibitory effect on parasite invasion. Heparan sulfate-deficient cells were less susceptible to C. parvum infection. We further identified 31 parasite proteins that potentially interact with heparin. Of these, we confirmed that C. parvum elongation factor 1α (CpEF1α), which plays a role in C. parvum invasion, binds to heparin and to the surface of HCT-8 cells. Our results further our understanding of the molecular basis of C. parvum infection and will facilitate the development of anti-cryptosporidial agents.
The genus Cryptosporidium is an intracellular parasite in apicomplexan1, which comprises 30 species classified based on their host specificity2. Cryptosporidium parvum can cause serious watery diarrhea in human and other mammals3. Most immuno-competent individuals experience self-limited diarrhea that resolves within 1–2 weeks4; however many immuno-compromised patients, such as patients with AIDS, can experience prolonged diarrhea that becomes life-threatening4.
C. parvum is also a problem in the farming industry; it is one of the most common enteropathogens in young calves, sheep, and goats3. Although most infected calves are asymptomatic in the absence of co-infection with viruses, bacteria, or other parasitic pathogens, cryptosporidiosis still causes economic losses for farmers5.
To date, several substances, including paromomycin, nitazoxanide, and lasalocid, have been shown to have anti-cryptosporodial activity. Paromomycin, an aminoglycoside, reduces oocyst excretion and stool frequency in immuno-compromised patients6. Nitazoxanide is only the drug approved by the FDA7 for the treatment of cryptosporidiosis; it effectively eradicates C. parvum oocysts from stool and resolves the diarrhea of both immuno-competent and -compromised individuals8. Lasalocid is an ionophorous antibiotic that reduces oocyst excretion in cattle9,10. However, all of these agents have limited effects on parasite growth, highlighting the urgent need for novel effective anti-cryptosporodial drugs.
C. parvum infection occurs when a host animal ingests C. parvum oocysts11. The oocysts undergo excystation and release sporozoites while passing through the stomach and duodenum due to the rise of temperature, bile salt, and digestive enzymes12. These sporozoites attach to intestinal epithelial cells, subsequently are embraced by the host cell membrane and develop into trophozoites in epicellular space13. This invasion is a critical step for the development of disease caused by C. parvum, yet there have been relatively few studies on the molecular basis of the host-parasite interactions that are necessary for C. parvum invasion of host cells12. We do know that Gal/GalNac is recognized by C. parvum p3014, and that the 85-kDa protein on Caco-2 cells is a receptor for C. parvum circum sporozoite-like antigen15. But the remaining host factors that interact with C. parvum sporozoites at the invasion step remain largely unknown.
C. parvum infects mainly the gastrointestinal tract16. However, sporozoites cannot directly interact with intestinal epithelial cells because glycocalyx, a filamentous layer of branched carbohydrates17, is present on these cells and act as a defensive barrier. Glycocalyx contains high levels of transmembrane mucin glycoproteins18, a type of proteoglycan. Mucin is the major component of the intestinal barrier19 and has been reported to reduce C. parvum attachment to intestinal epithelial cells in vitro20.
Proteoglycans (PGs) are composed of glycosaminoglycan (GAG) chains, which is a category of sulfated polysaccharides that are covalently bound to a protein core21. A variety of pathogens utilize them to invade their host cells22,23,24. Some sulfated polysaccharides have been shown to bind to several apicomplexan parasites, including Toxoplasma gondii and Plasmodium falciparum, and to inhibit their infection25,26,27,28,29. Therefore, we hypothesized that C. parvum interacts with GAGs on the host cells and that some sulfated polysaccharides may inhibit C. parvum infection. Despite many reports about the inhibitory effects of sulfated polysaccharides on various apicomplexan parasites, little is known about the interaction between C. parvum and sulfated polysaccharides14,30.
In this study, we evaluated the anti-cryptosporidial effects of five sulfated polysaccharides on parasite invasion, and found that heparin had the highest inhibitory effect on the C. parvum invasion of host cells. To gain further insight into the heparin-induced inhibitory mechanism of parasite invasion, we subsequently attempted to identify the C. parvum sporozoite proteins that physically bind to heparin.
Results
The effects of sulfated polysaccharides on C. parvum invasion of host cells
To examine the effects of sulfated polysaccharides on the invasion of host cells by C. parvum, we performed invasion inhibition assays with the following five sulfated polysaccharides: heparin, chondroitin sulfate A (CSA), dextran sulfate [DS high molecular weight (HMW) and DS low molecular weight (LMW)], and fucoidan (FDC) (Fig. 1A). All of these polysaccharides showed dose-dependent inhibitory effects on the C. parvum invasion of HCT-8 cells, inhibiting over 50% of invasion at a concentration of 100 μg/mL; however, the inhibitory effect differed among the polysaccharides. Of the five polysaccharides tested, heparin inhibited the most C. parvum invasion at the lower concentration of 1 μg/mL and its inhibitory effect was dose independent (Fig. 1B). Our data reveal that sulfated polysaccharides differ in their invasion inhibitory effects, with heparin having the highest and dose-dependent inhibitory effect on C. parvum invasion of HCT-8 cells among the sulfated polysaccharides tested. This result revealed that heparin competed with some factor(s) involved in the HCT-8 cell-parasite interaction in vitro.
C. parvum sporozoites are affected by heparin
To understand the mechanistic basis of the inhibitory effect of heparin on the invasion of culture cells by C. parvum, we conducted pre-incubation assays to elucidate whether heparin affects HCT-8 cells or parasites. No invasion inhibition was observed in the HCT-8 cells incubated with heparin prior to parasite infection (Fig. 2, left panel), whereas significant inhibition was observed in cells infected with parasites before incubation with heparin (Fig. 2, left panel). These results suggest that heparin competed with some factor(s) on the parasites rather than the HCT-8 cells, and that these parasites’ factors are involved in the invasion of HCT-8 cells in vitro.
Heparan sulfate is important for the efficient invasion by C. parvum
To determine whether heparin or heparin-like molecules are involved in the invasion of by C. parvum sporozoites, we compared the efficiency of parasite invasion of CHO pgs-D677 with that of wild-type CHO K1 cells. CHO pgsD-677 cells lacks both N-acetylglucosaminyl- and glucuronosyl-transferase, which are enzymes required for the polymerization of heparan sulfate or heparin31. Notably, heparin is mast cell polysaccharide32. Therefore, CHO pgsD-677 cells differ from CHO K1 cells in that they lack heparan sulfate, which is a kind of GAG and has a very similar structure to that of heparin. Cells were infected with C. parvum sporozoites, and the number of cells invaded by the parasites was compared. CHO pgsD-677 cells showed a statistically significant reduction in parasite invasion (27%) compared with that observed in wild-type CHO cells (Fig. 3). Thus, we demonstrated that heparan sulfate on the cell surface plays a role in invasion by C. parvum in vitro.
Identification of C. parvum-derived factors that interact with heparin
To identify parasite factors that interact with heparin, we conducted pull down assays with cell lysates of C. parvum sporozoites by using heparin-agarose beads, and subsequently analyzed the precipitated parasite proteins by using liquid chromatography tandem mass spectrometry (LC-MS/MS). We found bands specifically concentrated with molecular masses of around 120, 90, and 45 kDa in the precipitated fraction (Fig. 4A). The proteins in these three bands were gel-extracted and subjected to mass spectrometry analysis. For the heparin-binding proteins, we identified a total of 31 distinct proteins; 7 of these proteins were detected in the band with the molecular mass of 120 kDa, 11 proteins were detected for 90 kDa, and 13 for 45 kDa (Table 1).
Table 1. Heparin-binding proteins of C. parvum identified by using nano-LC/MS/MS.
Sample | Protein | MW(Da) | Scorea | Peptideb | Coveragec(%) |
---|---|---|---|---|---|
1 | hypothetical protein with a signal peptide | 111,402 | 741 | 29 | 35 |
conserved hypothetical protein | 123,651 | 442 | 26 | 31 | |
domain KOG1015, transcription regulator XNP/ATRX, DEAD-box superfamily, signal peptide | 91,962 | 429 | 25 | 32 | |
signal peptide, large secreted protein | 120,615 | 327 | 24 | 24 | |
hypothetical protein containing a signal peptide | 114,961 | 136 | 7 | 8 | |
signal peptide, large protein | 147,338 | 50 | 5 | 4 | |
phosphoenolpyruvate carboxylase | 130,753 | 34 | 1 | 0 | |
2 | acetaldehyde reductase plus alcohol dehydrogenase (AdhE) of possible bacterial origin | 94,675 | 509 | 25 | 38 |
Eft2p GTpase; translation elongation factor 2 (EF-2) | 93,215 | 501 | 26 | 38 | |
unconventional myosin | 91,421 | 390 | 22 | 25 | |
zincin/aminopeptidase N like metalloprotease | 105,843 | 382 | 21 | 25 | |
heat shock protein 90 (Hsp90), signal peptide plus ER retention motif | 89,137 | 336 | 19 | 31 | |
glycogen phosphorylase | 104,146 | 301 | 23 | 27 | |
KH domain protein | 91,196 | 220 | 9 | 11 | |
Hsp90 | 82,302 | 186 | 13 | 24 | |
conserved hypothetical protein | 102,374 | 102 | 3 | 4 | |
CDC48 like AAA ATPase ortholog | 90,504 | 43 | 2 | 2 | |
conserved hypothetical protein | 123,651 | 35 | 2 | 1 | |
3 | Actin | 42,147 | 401 | 23 | 61 |
elongation factor 1 alpha | 48,131 | 379 | 20 | 62 | |
phosphoglycerate kinase 1 | 43,286 | 274 | 13 | 39 | |
60S ribosomal protein-like, putative | 43,224 | 224 | 13 | 44 | |
hypothetical protein | 34,486 | 198 | 11 | 28 | |
hypothetical protein, signal peptide, predicted secreted protein | 40,831 | 178 | 8 | 30 | |
conserved protein of possible plant or bacterial origin | 47,123 | 65 | 4 | 13 | |
elongation factor EF1-gamma (glutathione S-transferase family) | 43,061 | 47 | 3 | 7 | |
protein kinase, cAMP-dependent, catalytic chain | 45,424 | 44 | 2 | 4 | |
ATP-dependent RNA helicase, putative | 46,008 | 36 | 2 | 5 | |
protein disulfide isomerase, signal peptide, ER retention motif | 50,484 | 35 | 3 | 6 | |
membrane associated thioredoxin | 42,072 | 34 | 2 | 6 | |
26S proteasome regulatory subunit S10b like AAA + ATpase | 45,515 | 33 | 4 | 7 |
Heparin-binding proteins identified throughnano-LC/MS/MS analysis are listed. Proteins whose ion score were >31 are shown.
aProtein score. This number reflects the combined scores of all observed mass spectra that can bematched to amino acid sequenceswithin that protein. A higher score indicates a more confident match.
bThe number of peptides included in each identified protein.
cThe ratio of the sequence of the identified protein occupied by the found peptides.
To further categorize these proteins based on molecular function, we performed functional enrichment analysis by using Gene Ontology (GO) analysis. These 31 proteins were enriched for multiple biological processes, that is, translation, homeostasis, metabolism, and respiration (Fig. 4B). Of note, the most enriched GO category for the heparin-binding proteins was translational elongation (P value = 4.1 × 10−3), including elongation factor 1 alpha (EF1α, cgd6_3990) and translation elongation factor 2 (EF2, cgd8_2930). Thus, we identified 31 parasite proteins with the potential to interact with heparin that are involved in diverse biological processes.
C. parvum elongation factor 1α (CpEF1α) is a heparin ligand
Among the parasite proteins that precipitated with heparin-agarose beads, C. parvum EF1α (CpEF1α) and EF2 belong to the most enriched GO category. Matsubayashi, M. et al. have previously showed that CpEF1α plays a role in the invasion and could be a potential protective antigen of C. parvum33, yet its host receptor has not been identified. We focused on CpEF1α and tested whether it directly interact with heparin. The GST-fusion CpEF1α was expressed at the expected molecular weight of 74 kDa in E. coli, was purified by GST beads, incubated with heparin-agarose beads, and its binding was assessed by silver staining. Actin was selected as a negative control because it did not belong to any GO categories and is often detected by mass spectrometry due to its abundance as a house-keeping gene. As we expected, a 68-kDa protein representative of GST-fused CpActin was scarcely pulled down with heparin-agarose beads (Fig. 5, right panel). By contrast, GST-fused CpEF1α was precipitated with heparin-agarose beads and a clear band was observed at the 74 kDa position (Fig. 5, left panel). Thus, we demonstrated that CpEF1α directly binds to heparin.
Finally, to investigate the biological interaction between CpEF1α and the receptor on the surface of the HCT-8 cell, the number of HCT-8 cells that binds to rCpEF1α was counted by using flow cytometry. Prior to binding assay, recombinant rCpEF1α and rGST was purified by ultrafiltration and the expression of the recombinant proteins were confirmed by silver staining and immunoblot. rGST served as a negative control. The HCT-8 cells incubated with rCpEF1α showed more fluorescence intensity than that observed for cells incubated with rGST (Fig. 6B). We observed statistically significant differences in the fluorescence intensity between the cells incubated with rGST and those incubated with rCpEF1α (P < 0.05), demonstrating that rCpEF1α binds to HCT-8 cells.
Discussion
Here, we evaluated the inhibitory effect of sulfated polysaccharides on the invasion of HCT-8 cells by C. parvum, and found that heparin was the most effective inhibitor of C. parvum invasion among the five sulfated polysaccharides tested. To our knowledge, this is the first report of the effect of heparin on C. parvum invasion. We also showed that heparin competes with some factor(s) involved in C. parvum sporozoite invasion. In addition, we showed that heparin does not affect the HCT-8 cells but rather the C. parvum sporozoites. We further identified 31 parasite proteins that interact with heparin by using pull-down assays followed by mass spectrometry. We confirmed the binding of CpEF1α with a heparin-like molecule on the surface of HCT-8 cells. Taken together, our data suggest that a heparin-like molecule is important for the efficient invasion of HCT-8 cells by C. parvum sporozoites.
We observed a discrepancy in the inhibition efficacy of parasite invasion by heparin between the invasion inhibition assay and the pre-incubation assay. While 65% of parasite invasion was blocked by 1 μg/mL heparin in the invasion inhibition assay, only 18% was blocked in the pre-incubation assay. This discrepancy could be attributed to the amount of heparin present in the medium. In the former experiment, heparin was abundant in the medium and bound to sporozoites when the sporozoites were inoculated. By contrast, in the latter experiment, only bound heparin was present because the sporozoites were washed three times after pre-incubation with heparin and then inoculated. In other words, the free heparin present in the medium might have contributed to the inhibition of parasite invasion of host cells. Heparin may, therefore, bind to two different types of C. parvum sporozoite factor: surface proteins of sporozoites and secreted proteins involved in the invasion of the host cells by the sporozoites, resulting in efficient invasion inhibition.
The CHO pgsD-677 cell line was used as a heparan sulfate-deficient cell in our study. This cell line was less susceptibility to C. parvum sporozoite invasion than were wild-type cells. This cell line, however, expresses 3- to 4-fold higher levels of chondroitin sulfate than do wild-type cells31. Despite these higher levels of chondroitin sulfate, this cell line was much less susceptible to parasite invasion (Fig. 1A), indicating that heparan sulfate plays an important role in C. parvum invasion.
In our experiments, heparin did not completely inhibit C. parvum infection. Additionally heparan sulfate-deficient cells were less susceptibility to C. parvum. These results suggest heparan sulfate is not the sole receptor of C. parvum. Namely, other factors could cooperate to attach and invade into host cells. However, heparan sulfate is common molecule to mammals and this could help C. parvum is parasitic on many kinds of mammals. Therefore, heparan sulfate could be important molecule for infection and heparin is noticeable substance.
Eukaryotic EF1α (eEF1α) is involved in the first step of translation and elongation by binding and delivering aa-tRNAs to the A site of the ribosome34. In addition, eEF1-α has a multipleother functions35, including interaction with the actin cytoskeleton36 and modulation of microtubules in a Ca2+/CaM-dependent manner in mammalian cells37. By contrast, CpEF1α is reported to localize to the apical region of sporozoites, and play an essential role in invasion of sporozoites33. However, the binding partner of CpEF1α has not yet known. In the present study, we identified heparin as a CpEF1α-binding partner, and confirmed that recombinant CpEF1α bound to heparin and HCT-8 cells in vitro. Our results thus further our understanding of host-parasite interactions that are essential for parasite invasion of host cells.
Studies of various pathogens, including parasites27,38,39,40, viruses41,42,43, and bacteria44,45,46, strongly indicate that heparin binds to a range of microorganism proteins. Furthermore, heparin is known to inhibit the infection of various kinds of pathogen41,43,47,48. Most of the existing anti-cryptosporidial medicines are antibiotics or ionophores6,7,8,9,10. But these medicines have side effects and there is little information about safe dosages. Our study showed that heparin has an inhibitory effect on C. parvum infection. Although heparin is a sulfated polysaccharide, it can be synthesized in Escherichia coli49,50. Therefore, heparin could serve as a new type of anti-cryptosporidial agent. For clinical use, experimental testing in both humans and livestock is necessary. In addition, there are potential concerns regarding drug delivery and side effects. Ingested heparin could be digested in the stomach and not reach the small intestine. Therefore, it may be necessary to protect the heparin molecule with some kind of capsule. Moreover, heparin has anticoagulant effects51, suggesting that it could affect the blood coagulation system if ingested as a drug. A possible plan to utilize heparin is employing chemically-modified heparins52 which exhibit attenuated anticoagulant activity but, which keep an ability to inhibit C. parvum infection. If this substance is made practical, our research will contribute to progression of the treatment for cryptosporidiosis.
In summary, we revealed that heparin inhibits C. parvum invasion of host cells. We identified CpEF1α as a heparin-binding protein and characterized its heparin-binding property and affinity to HCT-8 cells. These results suggest that CpEF1α interacts with heparan sulfate on host cells and that this interaction is important for host cell invasion. Our findings help further our understanding of the molecular basis of C. parvum invasion and are of value for the development of novel anti-cryptosporidial agents.
Methods
Cells and parasites
Human ileocecal colorectal adenocarcinoma (HCT-8) cells (obtained from the American Type Culture Collection (ATCC), VA, USA) were maintained in RPMI-1640 medium (Sigma-Aldrich, MO, USA) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 15 mM HEPES, 50 units/mL penicillin, and 50 μg/mL streptomycin. Wild-type CHO-K1 cells, and CHO D-677 cells (obtained from ATCC) were maintained in Ham’s F-12 medium (Invitrogen, CA, USA) supplemented with 10% fetal bovine serum, 50 units/mL penicillin, and 50 μg/mL streptomycin. All cultures were maintained at 37 °C in a humidified atmosphere containing 5% CO2.
C. parvum oocysts, strain HNJ-1, were kindly provided by Dr. K. Yagita (National Institute of Infectious Diseases). Oocysts were maintained by passage in experimentally infected nude mice (SLC, Shizuoka, Japan) and purified from feces by using discontinuous sucrose and cesium chloride gradients as described previously53.
Sporozoites excystation
C. parvum oocysts were treated with 10% (v/v) purelox (OyaloxCo.Ltd., Tokyo, Japan) for 10 min on ice, and then washed three times with phosphate buffered saline (PBS) by centrifugation at 7,000 rpm for 2 min at 4 °C. Purelox-treated and washed oocysts were treated with 0.1 M NaH2PO4-HCl (pH 2.0) for 30 min at 37 °C and then washed twice. The oocysts were further excysted in the PBS containing 0.75% sodium taurocholate and 0.25% trypsin for 1 h at 37 °C. Excysted sporozoites were separated from oocysts by filtration through a 5-μm pore-size PVDF filter (Merck Millipore, Darmstadt, Germany) and then used in the study. Oocysts and sporozoites were counted with microscopy using hemocytometer.
Infection inhibition assay
The following five sulfated polysaccharides were used in this study: heparin, chondroitin sulphate A (CSA), dextran sulfate [Molecular weight: 6.5–10 kDa (DS (LMW)], dextran sulfate [MW > 50 kDa (DS (HMW)], and fuccoidan (FCD). These polysaccharides were purchased from Sigma-Aldrich. A total of 2.5 × 105 HCT-8 or CHO cells were seeded in an 8-well chamber slide (Thermo Fisher Scientific Inc., MA, USA) and incubated overnight. The cells were then infected with 2.5 × 106 C. parvum sporozoites in RPMI-1640 medium containing each sulfated polysaccharide for 3 h. Cells were washed with the medium three times, and further incubated for 3 h. The cells were washed with PBS three times and then stained with Sporo-Glo (Waterborne Environmental, Inc., VA, USA) after fixation with ice-cold 100% methanol, and the number of parasites left in the HCT-8 cells or CHO cells was counted per 100 fields of view with 400 magnification by means of fluorescence microscopy using Axio Vert.A1 (Zeiss, Oberkochen, Germany).
Pre-incubation assay
C. parvum sporozoites or HCT-8 cells were incubated in RPMI-1640 medium containing heparin for 1 h prior to infection. Sporozoites or HCT-8 cells were washed with the medium without heparin three times, and subsequently mixed with HCT-8 cells or sporozoites, respectively, for 3 h. The number of parasites left in the cells was counted by following the protocol described above.
Plasmids
3.0 × 108 C. parvum, strain HNJ-1, sporozoites were used for DNA extraction. The sporozoite genomic DNA was extracted by using the QIAamp DNA Micro Kit (QIAGEN, Venlo, Netherlands) according to the manufacturer’s instructions. CpEF1α open reading frame was amplified by PCR with a pair of primers [forward, CpEF1-α-EcoRI-F (5’-ACT GAA TTC ATG GGT AAG GAA AAG ACT C-3’), and reverse, CpEF1α-NotI-R (5’-ACT GCG GCC GCT TAC TTC TTC TTG GAA GTG G-3)] that provided EcoRI and NotI restriction sites. The C. parvum actin (CpActin) open reading frame was amplified by PCR with a pair of primers [forward, CpActin-SalI-F (5’-ACT GGT CGA CTC ATG AGT GAA GAAGAA ACA C-3’), and reverse, CpActin-NotI-R (5’-ACT GCG GCC GCT TAG AAG CAC TTT CTG TG-3)] that provided SalI and NotI restriction sites. The amplified fragments of CpEF1α, and CpActin were digested with EcoRI/NotI and SalI/NotI, respectively, and were cloned into the pGEX-6P-1 vector (GE Healthcare UK Ltd, Buckinghamshire England) by using a DNA ligation kit (TAKARA BIO INC., Shiga, Japan) to express a glutathione S-transferase (GST) fusion protein.
Expression, purification, and concentration of GST fusion proteins
The resulting plasmids and pGEX-6P-1were transformed into competent cells of E. coli strain BL21. The recombinant fusion proteins, designated rCpEF1α, rCpActin, and rGST, were expressed following induction with 0.25 mM isopropyl β-D-1-thiogalactopyranoside (Wako Pure Chemical Industries, Ltd., Osaka, Japan). E. coli cell cultures expressing recombinant proteins were centrifuged at 5,000 rpm for 30 min, and lysed with lysis buffer [40 mMTris-HCl (pH 7.5), 150 mM NaCl, 1% TritonX-100, complete proteinase inhibitor cocktail (Roche)]. Cell lysates were subsequently centrifuged at 10,000 rpm for 10 min, and the supernatants containing recombinant protein were mixed with a 50% slurry of glutathione-sepharose beads (BD bioscience, NJ, USA) at room temperature for 30 min. The beads were washed with PBS three times and eluted with elution buffer (10 mM glutathione and 500 mM Tris-HCl, pH 8.0).
Pull-down assay
To identify the parasite proteins that interact with heparin, excysted C. parvum sporozoites were lysed with 1% octylglucoside (OGS, Sigma-Aldrich) in PBS overnight at 4 °C14, and centrifugation at 10,000 rpm for 25 min. The supernatants were mixed with heparin-agarose beads (Sigma-Aldrich) at 4 °C for 1 h. The beads were then washed with 0.1% OGS in PBS three times.
To confirm the interaction of parasite proteins with heparin, the purified recombinant proteins were mixed with heparin-agarose beads (Sigma-Aldrich) at 4 °C for 1 h. The beads were washed with PBS three times. The beads were then boiled for 5 min in equal volumes of 2 × sample buffer that contained 0.125 M Tris (pH 6.8), 4% SDS, 20% glycerol, and 10% 2-mercaptoethanol.
Silver staining, mass spectrometry and mascot search
The proteins eluted from the beads described above were separated by SDS-PAGE and then silver stained. The gel was stained by using the Ez stain silver kit (ATTO, Tokyo, Japan). Protein bands were excised from the gels, digested with trypsin and subjected to nano-LC/MS/MS analysis by following the standard protocol using QSTAR XL (Applied Biosystems, CA, USA) and Bio NanoLC (KYA Technologies, Tokyo, Japan). Protein digestion, nano-LC/MS/MS analysis, and the mascot search were conducted by Japan Proteomics (Sendai, Japan).
Functional enrichment analyses
To functionally categorize the proteins identified in our study, the proteins were assigned to a GO grouping. GO analysis was carried out by using the Gene Ontology Enrichment embedded in the CryptoDB database (http://cryptodb.org/); Fisher’s exact P values were used to determine the GO terms that were significant (P < 0.05).
Flow cytometry
The purified rCpEF1α and rGST were concentrated by using Amicon Ultra filter units (50 K for rCpEF1α and 3 K for rGST) (Merck Millipore). The protein concentration was measured by using Protein Quantification Kit-Rapid (Dojindo laboratories, Kumamoto, Japan), and was diluted to 7.5 μM with elution buffer. Semi-confluent HCT-8 cells were washed twice, and treated with 500 μM EDTA in PBS for 5 min at 37 °C. Detached cells were washed with FACS buffer (PBS containing 2% fetal calf serum) by centrifugation at 1,500 rpm. Then 2 × 106 washed HCT-8 cells were incubated with 100 μL of 7.5 μM rCpEF1α or rGST for 2 h at 4 °C, and then washed twice with FACS buffer. The cells were then incubated with 100 μL of rabbit α-GST antibody (Sigma-Aldrich) at 1:1000 dilution for 30 min at 4 °C, washed with FACS buffer containing 2% FCS twice, incubated with 100 μL of Alexa 488-conjugated α-rabbit IgG goat antibody at 1:1000 dilution for 30 min at 4 °C, and washed with FACS buffer again. As a negative control, detached HCT-8 cells which were incubated with neither proteins nor antibodies were also prepared. The sample was then analyzed on BD FACSVerse (BD Bioscience) using BD FACSuite software (BD Biosciences). HCT-8 cells were gated on forward/side-light scatter to distinguish them from debris. Cells (10,000 events) were analysed by Alexa 488 channels.
Additional Information
How to cite this article: Inomata, A. et al. Heparin interacts with elongation factor 1α of Cryptosporidium parvum and inhibits invasion. Sci. Rep. 5, 11599; doi: 10.1038/srep11599 (2015).
Acknowledgments
We thank Susan Watson for editing the manuscript. We also thank Dr. Kenji Yagita (Protozoa Laboratory, Department of Parasitology, National Institute of Infectious Diseases) for providing us with C. parvum oocysts. This study was supported by Grants-in-Aids for Young Scientists, Exploratory Scientific Research on Innovative Areas (3308) from the Ministry of Education, Culture, Science, Sports, and Technology (MEXT) and for Research on global health issues from the Ministry of Health, Labour and Welfare of Japan, the Bio-oriented Technology Research Advancement Institution (BRAIN), The Akiyama Life Science Foundation, and the Program to Disseminate Tenure Tracking System from the Japan Science and Technology Agency (JST).
Footnotes
Author Contributions A.Inomata, F.M. and K.K. designed the experiments. A.Inomata and F.M. performed the C. parvum propagation and isolation. A.Inomata performed biological experiments and wrote the main manuscript. F.M., A.Ishiwa, R.T., H.T., T.S., F.K.R and T.H. contributed to the data analysis and discussion. K.K. edited the manuscript and supervised the study.
References
- Bouzid M., Hunter P. R., Chalmers R. M. & Tyler K. M. Cryptosporidium Pathogenicity and Virulence. Clin. Microbiol. Rev. 26, 115–134 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Slapeta J. Cryptosporidiosis and Cryptosporidium Species in Animals and Humans: A Thirty Colour Rainbow? Int. J. Parasitol. 43, 957–970 (2013). [DOI] [PubMed] [Google Scholar]
- Thompson R. C. A. et al. Cryptosporidium and Cryptosporidiosis. Adv. Parasitol. 59, 77–158 (2005). [DOI] [PubMed] [Google Scholar]
- Odonoghue P. J. Cryptosporidium and Cryptosporidiosis in Man and Animals. Int. J. Parasitol. 25, 139–195 (1995). [DOI] [PubMed] [Google Scholar]
- De Graaf D. C., Vanopdenbosch E., Ortega-Mora L. M., Abbassi H. & Peeters J. E. A Review of the Importance of Cryptosporidiosis in Farm Animals. Int. J. Parasitol. 29, 1269–1287 (1999). [DOI] [PMC free article] [PubMed] [Google Scholar]
- White A. C. et al. Paromomycin for Cryptosporidioisis in Aids - a Prospective, Double-Blind Trial J. Infect. Dis. 170, 419–424 (1994). [DOI] [PubMed] [Google Scholar]
- Davies A. P. & Chalmers R. M. Cryptosporidiosis. Br. Med. J. 339, 10 (2009). [DOI] [PubMed] [Google Scholar]
- Rossignol J. F. Ctyptosporidium and Giardia: Treatment Options and Prospects for New Drugs. Exp. Parasitol. 124, 45–53 (2010). [DOI] [PubMed] [Google Scholar]
- Sahal M., Karaer Z., Duru S. Y., Cizmeci S. & Tanyel B. Cryptosporidiosis in Newborn Calves in Ankara Region: Clinical, Haematological Findings and Treatment with Lasalocid-Na. Dtsch. Tierarztl. Wochenschr. 112, 203–208, 210 (2005). [PubMed] [Google Scholar]
- Murakoshi F. et al. Administration of Lasalocid-Na Is Preventive against Cryptosporidiosis of Newborn Calves. Vet. Rec. 175, 353 (2014). [DOI] [PubMed] [Google Scholar]
- Wilhelm C. L. & Yarovinsky F. Apicomplexan Infections in the Gut. Parasite Immunol. 36, 409–420 (2014). [DOI] [PubMed] [Google Scholar]
- Lendner M. & Daugschies A. Cryptosporidium Infections: Molecular Advances. Parasitology. 141, 1511–1532 (2014). [DOI] [PubMed] [Google Scholar]
- Valigurova A. et al. Cryptosporidia: Epicellular Parasites Embraced by the Host Cell Membrane. Int. J. Parasitol. 38, 913–922 (2008). [DOI] [PubMed] [Google Scholar]
- Bhat N., Joe A., PereiraPerrin M. & Ward H. D. Cryptosporidium P30, a Galactose/N-Acetylgalactosamine-Specific Lectin, Mediates Infection in Vitro. J. Biol. Chem. 282, 34877–34887 (2007). [DOI] [PubMed] [Google Scholar]
- Langer R. C., Schaefer D. A. & Riggs M. W. Characterization of an Intestinal Epithelial Cell Receptor Recognized by the Cryptosporidium parvum Sporozoite Ligand Csl. Infect. Immun. 69, 1661–1670 (2001). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Current W. L. & Garcia L. S. Cryptosporidiosis. Clin. Lab. Med. 11, 873–897 (1991). [PubMed] [Google Scholar]
- Merga Y., Campbell B. J. & Rhodes J. M. Mucosal Barrier, Bacteria and Inflammatory Bowel Disease: Possibilities for Therapy. Dig. Dis. 32, 475–483 (2014). [DOI] [PubMed] [Google Scholar]
- McGuckin M. A., Linden S. K., Sutton P. & Florin T. H. Mucin Dynamics and Enteric Pathogens. Nat. Rev. Microbiol. 9, 265–278 (2011). [DOI] [PubMed] [Google Scholar]
- Kato K. & Ishiwa A. Roles of Carbohydrates in the Infection Strategies of Enteric Pathogens. Trop Med Health. Trop. Med. Health. 43, 41–52 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chen X. M. & LaRusso N. F. Mechanisms of Attachment and Internalization of Cryptosporidium parvum to Biliary and Intestinal Epithelial Cells. Gastroenterology. 118, 368–379 (2000). [DOI] [PubMed] [Google Scholar]
- Kjellen L. & Lindahl U. Proteoglycans-Structures and Interactions. Annu. Rev. Biochem. 60, 443–475 (1991). [DOI] [PubMed] [Google Scholar]
- Chen Y., Gotte M., Liu J. & Park P. Microbial Subversion of Heparan Sulfate Proteoglycans. Mol. Cells. 26, 415–426 (2008). [PubMed] [Google Scholar]
- Rostand K. S. & Esko J. D. Microbial Adherence to and Invasion through Proteoglycans. Infect. Immun. 65, 1–8 (1997). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ghosh T. et al. Focus on Antivirally Active Sulfated Polysaccharides: From Structure-Activity Analysis to Clinical Evaluation. Glycobiology. 19, 2–15 (2009). [DOI] [PubMed] [Google Scholar]
- Ortega-Barria E. & Boothroyd J. C. A Toxoplasma Lectin-Like Activity Specific for Sulfated Polysaccharides Is Involved in Host Cell Infection. J. Biol. Chem. 274, 1267–1276 (1999). [DOI] [PubMed] [Google Scholar]
- Ishiwa A. et al. Effects of Dextran Sulfates on the Acute Infection and Growth Stages of Toxoplasma gondii. Parasitol. Res. 112, 4169–4176 (2013). [DOI] [PubMed] [Google Scholar]
- Kobayashi K. et al. Plasmodium falciparum Baebl Binds to Heparan Sulfate Proteoglycans on the Human Erythrocyte Surface. J. Biol. Chem. 285, 1716–1725 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Recuenco F. C. et al. Gellan Sulfate Inhibits Plasmodium falciparum Growth and Invasion of Red Blood Cells in Vitro. Sci. Rep. 4, 7 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Andrews K. T., Klatt N., Adams Y., Mischnick P. & Schwartz-Albiez R. Inhibition of Chondroitin-4-Sulfate-Specific Adhesion of Plasmodium falciparum-Infected Erythrocytes by Sulfated Polysaccharides. Infect. Immun. 73, 4288–4294 (2005). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Maruyama H., Tanaka M., Hashimoto M., Inoue M. & Sasahara T. The Suppressive Effect of Mekabu Fucoidan on an Attachment of Cryptosporidium parvum Oocysts to the Intestinal Epithelial Cells in Neonatal Mice. Life Sci. 80, 775–781 (2007). [DOI] [PubMed] [Google Scholar]
- Lidholt K. et al. A Single Mutation Affects Both N-Acetylglucosaminyltransferase and Glucuronosyltransferase Activities in a Chinese-Hamster Ovary Cell Mutant Defective in Heparan Sulfate Biosynthesis. Proc. Natl. Acad. Sci. U. S. A. 89, 2267–2271 (1992). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Esko J. D. & Lindahl U. Molecular Diversity of Heparan Sulfate. J. Clin. Invest. 108, 169–173 (2001). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Matsubayashi M. et al. Elongation Factor-1 Alpha Is a Novel Protein Associated with Host Cell Invasion and a Potential Protective Antigen of Cryptosporidium parvum. J. Biol. Chem. 288, 34111–34120 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Carvalho M. D. D., Carvalho J. F. & Merrick W. C. Biological Characteriztion of Various Forms of Elongationfactor-I from Rabbit Reticulocytes. Arch. Biochem. Biophys. 234, 603–611 (1984). [DOI] [PubMed] [Google Scholar]
- Sasikumar A. N., Perez W. B. & Kinzy T. G. The Many Roles of the Eukaryotic Elongation Factor 1 Complex. Wiley Interdiscip. Rev.-Rna. 3, 543–555 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Stapulionis R., Kolli S. & Deutscher M. P. Efficient Mammalian Protein Synthesis Requires an Intact F-Actin System. J. Biol. Chem. 272, 24980–24986 (1997). [DOI] [PubMed] [Google Scholar]
- Moore R. C., Durso N. A. & Cyr R. J. Elongation Factor-1 Alpha Stabilizes Microtubules in a Calcium/Calmodulin-Dependent Manner. Cell Motil. Cytoskeleton. 41, 168–180 (1998). [DOI] [PubMed] [Google Scholar]
- Azzouz N. et al. Toxoplasma gondii Secretory Proteins Bind to Sulfated Heparin Structures. Glycobiology. 23, 106–120 (2013). [DOI] [PubMed] [Google Scholar]
- Cortes L. M. D. et al. Leishmania (Viannia) braziliensis: Insights on Subcellular Distribution and Biochemical Properties of Heparin-Binding Proteins. Parasitology. 139, 200–207 (2012). [DOI] [PubMed] [Google Scholar]
- Love D. C., Esko J. D. & Mosser D. M. A Heparin-Binding Activity on Leishmania Amastigotes Which Mediates Adhesion to Cellular Proteoglycans. J. Cell Biol. 123, 759–766 (1993). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Copeland R. et al. Using a 3-O-Sulfated Heparin Octasaccharide to Inhibit the Entry of Herpes Simplex Virus Type 1. Biochemistry. 47, 5774–5783 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Liu J. & Thorp S. C. Cell Surface Heparan Sulfate and Its Roles in Assisting Viral Infectious. Med. Res. Rev. 22, 1–25 (2002). [DOI] [PubMed] [Google Scholar]
- Schulze A., Gripon P. & Urban S. Hepatitis B Virus Infection Initiates with a Large Surface Protein-Dependent Binding to Heparan Sulfate Proteoglycans. Hepatology. 46, 1759–1768 (2007). [DOI] [PubMed] [Google Scholar]
- AlvarezDominguez C., VazquezBoland J. A., CarrascoMarin E., LopezMato P. & LeyvaCobian F. Hose Cell Heparan Sulfate Proteoglycans Mediate Attachment and Entry of Listeria monocytogenes, and the Listerial Surface Protein Acta Is Involved in Heparan Sulfate Receptor Recognition. Infect. Immun. 65, 78–88 (1997). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wuppermann F. N., Hegemann J. H. & Jantos C. A. Heparan Sulfate-Like Glycosaminoglycan Is a Cellular Receptor for Chlamydia pneumoniae. J. Infect. Dis. 184, 181–187 (2001). [DOI] [PubMed] [Google Scholar]
- Liang O. D., Ascencio F., Fransson L. A. & Wadstrom T. Binding of Heparan Sulfate to Staphylococcus aureus. Infect. Immun. 60, 899–906 (1992). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Henry-Stanley M. J., Hess D. J., Erlandsen S. L. & Wells C. L. Ability of the Heparan Sulfate Proteoglycan Syndecan-1 to Participate in Bacterial Translocation across the Intestinal Epithelial Barrier. Shock. 24, 571–576 (2005). [DOI] [PubMed] [Google Scholar]
- Kobayashi K. et al. Analyses of Interactions between Heparin and the Apical Surface Proteins of Plasmodium falciparum. Sci. Rep. 3, 10 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- Li P. L. et al. Heparosan-Derived Heparan Sulfate/Heparin-Like Compounds: One Kind of Potential Therapeutic Agents. Med. Res. Rev. 33, 665–692 (2013). [DOI] [PubMed] [Google Scholar]
- Rusnati M. et al. Sulfated K5 Escherichia coli Polysaccharide Derivatives: A Novel Class of Candidate Antiviral Microbicides. Pharmacol. Ther. 123, 310–322 (2009). [DOI] [PubMed] [Google Scholar]
- Weitz J. I. Low-Molecular-Weight Heparins. New Engl. J. Med. 337, 688–698 (1997). [DOI] [PubMed] [Google Scholar]
- Yates E. A., Guimond S. E., & Turnbull J. E. Highly Diverse Heparan Sulfate Analogue Libraries: Providing Access to Expanded Areas of Sequence Space for Bioactivity Screening. J. Med. Chem. 47, 277–280 (2004). [DOI] [PubMed] [Google Scholar]
- Arrowood M. J. & Donaldson K. Improved Purification Methods for Calf-Derived Cryptosporidium parvum Oocysts Using Discontinuous Sucrose and Cesium Chloride Gradients. J. Eukaryot. Microbiol. 43, S89–S89 (1996). [DOI] [PubMed] [Google Scholar]